Pluri Says US NIAID Will Provide Company With $1.4M From July 1, 2024 To June 30, 2025; NIAID Exercised Its Option For Year Two Of The Three-year $4.2M Contract It Entered Into With Pluri In July 2023

The company will manufacture the PLX-R18 cell therapy and to conduct both in vitro and in vivo studies to develop PLX-R18 as a potential novel treatment for hematopoietic complications of the acute radiation syndrome (H-ARS).